{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:21:33Z","timestamp":1771305693155,"version":"3.50.1"},"reference-count":24,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>Although the majority of people with multidrug-resistant\/rifampicin-resistant TB (MDR\/RR-TB) can now be successfully treated with all-oral shorter regimens, rising rates of resistance to the components in these regimens are a growing global challenge. The drug development pipeline for TB has more novel compounds in phase 2 trials than ever before, and accessing these agents through systematic compassionate use programmes is an ethical and public health imperative. There is more than a decade of successful experience with compassionate use for MDR\/RR-TB, resulting in benefits for people with MDR\/RR-TB, novel chemical entity developers, providers, and programmes. Although there are some arguments for delaying access to the new TB drugs in the pipeline, we present reasons why such access should be an urgent priority for all TB stakeholders.<\/jats:p>","DOI":"10.5588\/ijtldopen.25.0644","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T11:08:01Z","timestamp":1765796881000},"page":"701-704","source":"Crossref","is-referenced-by-count":1,"title":["The time is now: making the case for compassionate use\/pre-approval access to new TB drugs"],"prefix":"10.5588","volume":"2","author":[{"given":"A.","family":"Reuter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Stillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.S.","family":"Thi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Motta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.B.","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mesic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mbenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Guglielmetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gebhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"DeCroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Furin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026011502215936000_2.12.701.1","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2025 update. Geneva: WHO, 2025."},{"key":"2026011502215936000_2.12.701.2","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.lanepe.2025.101380","article-title":"TBnet\/ESGMYC XDR-TB study group. Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study","volume":"56","author":"Kherabi","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"10","key":"2026011502215936000_2.12.701.3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1473-3099(25)00218-X","article-title":"Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study","volume":"25","author":"Mdlenyani","year":"2025","journal-title":"Lancet Inf Dis"},{"issue":"1","key":"2026011502215936000_2.12.701.4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1186\/s12879-022-07861-x","article-title":"Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis","volume":"22","author":"Pai","year":"2022","journal-title":"BMC Inf Dis"},{"issue":"12","key":"2026011502215936000_2.12.701.5","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Mic"},{"key":"2026011502215936000_2.12.701.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2404644"},{"key":"2026011502215936000_2.12.701.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604544"},{"issue":"4","key":"2026011502215936000_2.12.701.8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5588\/pha.23.0033","article-title":"Addressing the needs of people with extensively drug-resistant TB through pre-approval access to drugs and research","volume":"13","author":"Stillo","year":"2023","journal-title":"Public Heatlh Action"},{"key":"2026011502215936000_2.12.701.9","unstructured":"McKenna L , Treatment Action Group . Pipeline report: tuberculosis. New York, NY, USA: Treatment Action Group, 2025. https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2025\/08\/pipeline_TB_Treatment_2025_final.pdf."},{"issue":"4","key":"2026011502215936000_2.12.701.10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(24)00601-7","article-title":"Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial","volume":"25","author":"Dawson","year":"2025","journal-title":"Lancet Inf Dis"},{"issue":"2","key":"2026011502215936000_2.12.701.11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5588\/ijtld.12.0017","article-title":"Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis","volume":"17","author":"Horsburgh","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2026011502215936000_2.12.701.12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/2229-3485.173779","article-title":"Early access programs: benefits, challenges, and key considerations for successful implementation","volume":"7","author":"Patil","year":"2016","journal-title":"Perspect Clin Res"},{"key":"2026011502215936000_2.12.701.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01799-2016"},{"key":"2026011502215936000_2.12.701.14","unstructured":"World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO, 2014."},{"issue":"7","key":"2026011502215936000_2.12.701.15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5588\/ijtld.17.0840","article-title":"Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia","volume":"22","author":"Hewison","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"2026011502215936000_2.12.701.16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1183\/13993003.00705-2016","article-title":"Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges","volume":"48","author":"Tadolini","year":"2016","journal-title":"ERJ"},{"issue":"C","key":"2026011502215936000_2.12.701.17","first-page":"56","article-title":"Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives","volume":"32","author":"Lessem","year":"2015","journal-title":"IJID"},{"key":"2026011502215936000_2.12.701.18","unstructured":"European Medicines Agency . Compassionate use. Amsterdam, the Netherlands: European Medicines Agency, 2010. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compassionate-use."},{"issue":"5","key":"2026011502215936000_2.12.701.19","doi-asserted-by":"crossref","first-page":"2002483","DOI":"10.1183\/13993003.02483-2020","article-title":"Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update","volume":"7","author":"Ghosh","year":"2021","journal-title":"ERJ"},{"key":"2026011502215936000_2.12.701.20","unstructured":"United States Food and Drug Administration . Annual summary reporting requirements under the right to try act. Washington, DC., USA: United States Food and Drug Administration, 2022. https:\/\/www.federalregister.gov\/documents\/2022\/09\/14\/2022-19737\/annual-summary-reporting-requirements-under-the-right-to-try-act."},{"key":"2026011502215936000_2.12.701.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02020-19"},{"issue":"2","key":"2026011502215936000_2.12.701.22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5588\/ijtld.17.0793","article-title":"Has compassionate use ever sunk a drug?","volume":"22","author":"McAnaw","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026011502215936000_2.12.701.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00811-2"},{"issue":"3","key":"2026011502215936000_2.12.701.24","doi-asserted-by":"crossref","first-page":"1601699","DOI":"10.1183\/13993003.01699-2016","article-title":"Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India","volume":"49","author":"Udwadia","year":"2017","journal-title":"ERJ"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.25.0644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:24:35Z","timestamp":1768472675000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.25.0644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.5588\/ijtldopen.25.0644"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.25.0644","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}